|
UPCOMING EVENTS
Gynecologic Cancer Care
Wednesday, December 10
6:30 - 8 pm
Dr. Stephanie Wethington, Director for Gynecologic Oncology at Washington Hospital Center, will talk about the importance of individualized care and the multiple approaches available including open abdominal, laparoscopic and robotic surgery; fertility-sparing; chemo; and targeted therapies.
Hope Connections for Cancer Support
Beaumont House at FASEB
9650 Rockville Pike
Bethesda, MD 20814
301-634-7500
info@hopeconnectionsforcancer.org
Ovarian Research Cancer Fund Event
Join us for a presentation by Jeff Boyd, PhD, who will provide updates on the current state of science on developing new precision therapeutics for ovarian cancer. Dr. Boyd will also answer your questions. Dr. Boyd is an international expert in translational research and has particular expertise in the genetics of ovarian, endometrial and breast cancer.
To register for "Precision Therapeutics for Ovarian Cancer: Where Are We?" click here:
A Radioshow for Cancer Patients
Listen to "Frankly Speaking About Cancer" every Tuesday at 4pm eastern time (1pm pacific time). The host is Kim Thiboldeaux, President and CEO of the Cancer Support Community, stives to empower her listeners to live well with cancer. Click here to visit the website. You can also find past episodes available for listening!
|
|
|
|
|
OGCC/RHONDA'S CLUB ACTIVITIES
Tribute to Frances Stolusky
Our friend and colleague, Fran Stolusky, passed away on November 4, 2014. Fran will always be remembered as an active and long-term member of the board of Rhonda’s Club and as the long-time manager of our Survivors Teaching Students classes. She trained, scheduled and mentored scores of women to share their stories of survival with medical students with the goal of increasing awareness and early detection. Every year, she helped bring that message to more than 400 students. Fran also participated in countless health fairs, fundraising walks, conferences and other outreach programs to further our mission to battle gynecologic cancers by raising public awareness of symptoms, educating survivors and medical professionals, and supporting research to improve quality of life, and find the cures. Fran was always there, and she always got the job done.
And Coming in November….
Saturday, November 1-Sunday, November 2: Foundation for Women’s Cancer Gynecologic Cancer Awareness weekend.
On Saturday, November 1: a free survivors gynecologic cancer seminar with leading U.S. experts in gynecologic cancer research and treatment. Registration available in early October. Learn more at endwomenscancer.org.
view our calendar of events > |
|
|
|
|
MEDICAL NEWS
A study found that robotic surgery for benign gynecologic procedures had a higher rate of complication than conventional surgery, and was more costly.
November 14, 2014, the Food and Drug Administration announced the approval of Genentech’s Avastin (bevacizumab) in combination with chemotherapy for women with platinum-resistant recurrent ovarian cancer. The approval was based on the results of a Phase III clinical trial which showed women who received Avastin with chemotherapy had a 62% improvement in progression free survival (disease worsening) as compared to those who received chemotherapy alone.
The combination of the antiangiogenesis drug bevacizumab and the vascular-disrupting agent fosbretabulin is superior to bevacizumab alone in the treatment of recurrent ovarian, tubal, and peritoneal cancer, according to an oral presentation made at the biennial meeting of the International Gynecologic Cancer Society. A study found significant improvement in progression-free survival among patients treated with the combination of bevacizumab and fosbretabulin versus bevacizumab alone, with a median improvement of 2.5 months.
Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Patients given the drug, trebananib, along with a chemotherapy agent paclitaxel, experienced overall survival of 19.3 months, compared with 18.3 months for the placebo group. Analysts said oncologists expect the drug to have little or no benefits in terms of overall survival and FDA approval seems unlikely.
more resources > |
|
|
